Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SenL-T7 CAR T Cells in R/R CD7+ T-ALL/T-LBL
NCT04916860Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SENL101 in T-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Status: unknown.
02
Drugs
SENL101
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04916860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916860.